Wednesday, April 11, 2018 2:58:43 PM
Posted by Joseph McCarthy on Apr 11th, 2018 // No Comments
Tonix Pharmaceuticals (NASDAQ: TNXP) is one of 484 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Tonix Pharmaceuticals to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
Profitability
This table compares Tonix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -74.46% -69.58%
Tonix Pharmaceuticals Competitors -3,102.68% -152.82% -26.71%
Risk & Volatility
Tonix Pharmaceuticals has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals’ rivals have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.
Earnings and Valuation
This table compares Tonix Pharmaceuticals and its rivals revenue, earnings per share and valuation.
Gross Revenue Net Income Price/Earnings Ratio
Tonix Pharmaceuticals N/A -$21.12 million -1.05
Tonix Pharmaceuticals Competitors $2.03 billion $132.97 million -3.45
Tonix Pharmaceuticals’ rivals have higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
15.4% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Tonix Pharmaceuticals and its rivals, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals 0 0 4 0 3.00
Tonix Pharmaceuticals Competitors 2761 8456 21244 566 2.59
Tonix Pharmaceuticals presently has a consensus target price of $8.33, indicating a potential upside of 174.12%. As a group, “Pharmaceutical preparations” companies have a potential upside of 44.66%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Tonix Pharmaceuticals is more favorable than its rivals.
Summary
Tonix Pharmaceuticals beats its rivals on 7 of the 13 factors compared.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
__________________________________________________
https://theenterpriseleader.com/2018/04/11/head-to-head-review-tonix-pharmaceuticals-tnxp-versus-the-competition.html
Interesting, but can't verify the info.
TNXP
Recent TNXP News
- Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering • GlobeNewswire Inc. • 03/28/2024 01:32:56 PM
- Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024 • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:05:22 PM
- Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT • GlobeNewswire Inc. • 03/07/2024 02:37:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:06:09 PM
- Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:05:29 PM
- Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:05:37 PM
- Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:08:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:07:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:06:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:05:49 PM
- Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:06:21 PM
- Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:07:07 PM
- Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM